Welcome to our dedicated page for Teva Pharmaceutical Industries SEC filings (Ticker: TEVJF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Teva Pharmaceutical Industries's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Teva Pharmaceutical Industries's regulatory disclosures and financial reporting.
Teva Pharmaceutical Industries’ interim Chief Legal Officer, Brian Savage, reported several equity compensation transactions in Teva ordinary shares and restricted share units on March 4, 2026. He acquired ordinary shares through the vesting and exercise of restricted share units and also received a new restricted share unit award.
On that date he acquired ordinary shares via derivative exercises totaling 4,744 shares and 3,466 shares, and was granted 11,280 restricted share units, each representing a right to one ordinary share or its cash value at settlement. To satisfy tax withholding obligations from these vestings, he sold 1,489 shares and 1,186 shares in open-market transactions at a weighted average price of $32.4645 per share. After these transactions, he directly owned 8,461 ordinary shares.
Teva Pharmaceutical Industries’ Chief Accounting Officer, Amir Weiss, reported equity-based compensation activity on March 4, 2026. He exercised previously granted restricted share units (RSUs), converting 10,679 RSUs from a 2022 grant and 5,650 RSUs from a 2024 grant into the same number of ordinary shares at no cash cost.
Weiss also received a new award of 11,280 RSUs granted on March 4, 2026, scheduled to vest in four equal installments of 2,820 units on March 4 of 2027, 2028, 2029 and 2030. Following these transactions, he directly owned 27,158 ordinary shares and 11,280 RSUs, reflecting increased equity exposure with no reported share sales.
Teva Pharmaceutical Industries Limited submitted a Form 144 reporting the sale of 17,295 ordinary shares under Rule 144. The filing references a Restricted Share Unit award vesting dated 03/05/2025 and lists 03/05/2026 and the NYSE in the securities table.
Teva Pharmaceutical Industries Limited filed a Form 144 reporting the proposed sale of 14,150 ordinary shares with an aggregate market value of $448,107.86. The shares are tied to a Restricted Share Unit Award with vesting/acquisition noted 03/05/2025, and the filing shows a transaction date of 03/05/2026, handled through Citigroup Global Markets.
Brian Savage reports proposed sales of Teva ordinary shares and an upcoming RSU vesting. The filing lists three dispositions: 450 shares on 01/30/2026 for $15,178.95, 1,000 shares on 12/12/2025 for $29,910.70, and 1,274 shares on 03/03/2026 for $41,226.51.
The notice also shows 3,580 restricted share units vesting on 03/05/2026 described as a compensation award.
Teva Pharmaceutical Industries Limited submitted a Form 144 reporting proposed and recent ordinary share activity. The filing lists 17,819 ordinary shares tied to a restricted share unit award vesting on 03/05/2026 through Citigroup Global Markets Inc. It also reports 9,908 ordinary shares sold on 03/04/2026 for $321,658.26.
Teva Pharmaceutical Industries Ltd. insider Richard Francis reported sales of 447,678 ordinary shares on 02/17/2026 for $15,324,799.05, 442,935 shares on 03/03/2026 for $14,333,332.31, and 23,393 shares on 03/04/2026 for $759,442.05.
The filing also shows a Restricted Share Unit award vesting of 42,452 ordinary shares on 03/05/2026 reported as compensation.
Teva Pharmaceutical Industries Limited reports Form 144 sale notices for insider Eric Hughes. The filing lists two transactions: 80,762 ordinary shares sold on 03/03/2026 for $2,613,450.24 and 11,277 ordinary shares sold on 03/04/2026 for $366,102.17. The filing also references 19,654 restricted share units vesting on 03/05/2026.
Teva Pharmaceutical Industries submitted a Form 144 notice reporting a proposed sale of 17,295 ordinary shares (ordinary shares to be sold through Citigroup Global Markets Inc.). The filing lists Richard Daniell as the selling person and shows earlier dispositions in the prior three months: 115,468 shares on 12/09/2025, 128,985 shares on 03/03/2026, and 91,345 shares on 03/04/2026, with corresponding gross proceeds included in the excerpt.
TEVA Pharmaceutical Industries Chief Accounting Officer Amir Weiss exercised 5,179 Restricted Share Units on March 3, 2026, converting them into 5,179 Ordinary Shares at a reported price of $0.0000 per share. Following the conversion, he held 10,829 Ordinary Shares directly and 5,180 restricted share units remain scheduled to vest on March 3, 2027. The restricted share units were originally granted on March 3, 2023, with 5,179 units vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026. The Ordinary Shares may be represented by American Depositary Shares, each currently representing one Ordinary Share.